Lipella Pharmaceuticals (LIPO) - 2023 Q3 - Quarterly Report
Lipella Pharmaceuticals (LIPO)2023-11-14 11:14UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) | Delaware | 20-2388040 | | --- ...